Skip to main content

Nivolumab + chemotherapy in previously untreated stage III or IV Hodgkin lymphoma

Intervista a Alex Francisco Herrera By 4 Giugno 2023No Comments
Dai congressi

The SWOG S1826 trial could change the treatment of classic Hodgkin lymphoma forever. Why and how? We asked Alex Francisco Herrera (Associate Professor, Division Of Lymphoma – City of Hope National Medical Center, Duarte) at ASCO 2023, in Chicago. He explained us how N-AVD improved PFS vs BV-AVD in pts with AS HL.